Recombinant Human YAP1 GST (N-Term) Protein

This product is produced by and distributed for Abnova, a company based in Taiwan.

The transcriptional coactivator Yes-associated protein (YAP), also known as Yes-associated protein 1 (YAP1), Yes-Associated Protein YAP65 Homolog, Protein Yorkie Homolog and YAP65 has a theoretical molecular weight of 65 kDa. The YAP1 gene encodes the human ortholog of chicken YAP protein which binds to the SH3 domain of the Yes proto-oncogene product. YAP1 shares homology with the WW domain of transcriptional co-activator with PDZ-binding motif (TAZ), which functions as a transcriptional co-activator by binding to the PPXY motif present in transcription factors and is likely involved in protein-protein interaction. YAP has been identified as a core regulatory mechanism that blocks mammalian glial cell proliferation and cellular reprogramming following damage (1).

YAP plays a role in the development and progression of multiple cancers as a transcriptional regulator of the Hippo signaling pathway. YAP1 encodes a nuclear effector of the Hippo signaling pathway which is involved in development, growth, repair, and homeostasis to play a pivotal role in controlling cell growth and organ size and has emerged as a key player in tumor suppression (2,3). Deregulation of the Hippo pathway causes tumor formation and malignancy, with YAP being a key oncogenic driver in liver carcinogenesis (2) and may function as a potential target for cancer treatment (3).

References

1. Rueda, E. M., Hall, B. M., Hill, M. C., Swinton, P. G., Tong, X., Martin, J. F., & Poche, R. A. (2019). The Hippo Pathway Blocks Mammalian Retinal Muller Glial Cell Reprogramming. Cell Rep, 27(6), 1637-1649.e1636. doi:10.1016/j.celrep.2019.04.047

2. Liu, A. M., Xu, M. Z., Chen, J., Poon, R. T., & Luk, J. M. (2010). Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets, 14(8), 855-868. doi:10.1517/14728222.2010.499361

3.Ye, S., & Eisinger-Mathason, T. S. (2016). Targeting the Hippo pathway: Clinical implications and therapeutics. Pharmacol Res, 103, 270-278. doi:10.1016/j.phrs.2015.11.025

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: In vitro, WB.

Showing Publications 1 - 5 of 5.

Publications using H00010413-P01	Applications	Species
Khalil MI, Ghosh I, Singh V et al. NEK1 Phosphorylation of YAP Promotes Its Stabilization and Transcriptional Output Cancers 2020-12-07 [PMID: 33297404] (In vitro, Human)	In vitro	Human
Xiaodong F, Nadia A, Damiano R et al. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Cancer Cell. 2019-02-04 [PMID: 30773340]
Yao F, Zhou Z, Kim J et al. SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity Nat Commun 2018-06-11 [PMID: 29891922] (WB, Human)	WB	Human
Chang Ss, Yamaguchi H, Xia W et al. Aurora A kinase activates YAP signaling in triple-negative breast cancer. Oncogene 2016-09-05 [PMID: 27593935]
Zhao Y, Zhou W, Xue L et al. Nicotine Activates YAP1 through nAChRs Mediated Signaling in Esophageal Squamous Cell Cancer (ESCC). PLoS One. 2014-03-12 [PMID: 24621512]

Images	Ratings	Applications	Species	Date	Details
Enlarge	4 reviewed by: Verified Customer	In-vitro kinase assay		09/18/2020	View Summary Application Other Lot K6191 Comments The protein we obtained is very clean and not degraded. It was sent in dry ice with proper packaging. Comments Comments In-vitro kinase assay either with TLK1B or MK5 using 32P-ATP.

Array H00010413-P01

• YAP1 Antibodies
• YAP1 Proteins